Minimum Effective Volume of Local Anesthetic Using Ultrasound for Brachial Plexus Block
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the minimum effective volume of local anesthetic for interscalene brachial plexus block using ultrasound guidance and nerve stimulator guidance.
| Condition | Intervention | Phase |
|---|---|---|
|
Anesthesia |
Drug: bupivacaine 0.5% |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Determination of the Minimum Effective Volume of Local Anesthetic Using Ultrasound Guidance for Interscalene Brachial Plexus Block |
- ED95 of bupivacaine minimum effective volume [ Time Frame: ED95 ] [ Designated as safety issue: No ]The ED95 of bupivacaine minimum effective volume determination in interscalene brachial plexus block using ultrasound guidance. [ Time Frame: every 10 minutes until 30 minutes, after 4 hours and after 6 hours post-block ]
- Diaphragmatic Function [ Time Frame: Diaphragmatic ] [ Designated as safety issue: No ]Diaphragmatic Function (as assessed by diaphragmatic movement on ultrasound) [ Time Frame: after 30 minutes, 4 hours and 6 hours post-block ]
- Post-surgery analgesia [ Time Frame: Analgesia ] [ Designated as safety issue: No ]Post-surgery analgesia [ Time Frame: after 4 hours and 6 hours post-block ]
| Estimated Enrollment: | 33 |
| Study Start Date: | September 2009 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
-
Drug: bupivacaine 0.5%
This will be a single group assignment, double-blind, up-down sequential allocation study. Interscalene brachial plexus block (ISBPB) is a common nerve block given to patients who are undergoing shoulder surgery. This block has a low, but still significant, rate of complications. Reducing the volume of local anesthetic given during the block may allow some of these complications to be avoided. Participants will undergo ISBPB under ultrasound and nerve stimulator guidance. Patients will initially receive 15mL of local anesthetic (bupivacaine 0.5% with epinephrine). The volume used for each subsequent patient depends upon the success or failure of the previous patient's block - a failure will cause the volume given to increase by 1.0 mL, while a success will cause the volume to decrease by the same amount.
The goal of this study is to determine the minimum effective anesthetic volume of bupivacaine 0.5% providing anesthesia in patients when using ultrasound and nerve stimulator to guide placement of the block. The secondary outcome will be the evaluation of diaphragmatic function and post-surgery analgesia.
Eligibility| Ages Eligible for Study: | 21 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients receiving interscalene brachial plexus block for shoulder surgery
- Age between 21 and 65 years
- ASA physical status I/II
- Body mass index < 35 kg/m2
Exclusion Criteria:
- Chronic obstructive pulmonary disease
- Psychiatric history
- Allergy to bupivacaine
- Infection in the site of block
- Coagulation disorders
Contacts and Locations
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Luiz Fernando dos Reis Falcao, Ph.D., Federal University of São Paulo |
| ClinicalTrials.gov Identifier: | NCT01244932 History of Changes |
| Other Study ID Numbers: | UNIFESP-01 |
| Study First Received: | October 14, 2010 |
| Last Updated: | May 8, 2012 |
| Health Authority: | Brazil: Ethics Committee |
Additional relevant MeSH terms:
|
Anesthetics, Local Bupivacaine Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |
Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 13, 2013